Clinical trial
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying…
NCT00398528 · Neurognostics, Industry · Terminated
Key facts
| NCT number | NCT00398528 |
|---|---|
| Title | An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis |
| Official title | An fMRI Study of Treatment Optimization Recommendations Comparing Patients Changing Treatment From Glatiramer Acetate 20 mg qd SC (Copaxone®) to IFN-β-1a 30 Mcg qw IM (Avonex®) to Those Changing From to IFN-β-1a 30 Mcg qw IM (Avonex®) to Glatiramer Acetate 20 mg qd SC (Copaxone®) in a Multicenter… |
| Lead sponsor | Neurognostics, Industry |
| Status | Terminated |
| Study type | Observational |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Glatiramer acetate, (Copaxone®), IFN-β-1a, (Avonex®) |
| Enrollment | 48 |
| Start date | Sep 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | Nov 10, 2006 |
| Last update posted | Dec 5, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: